top of page
LA1_CD68op520_CD3_op570_CD8_op690_panCKAF750_20X -10.bmp

TruTumor Systems

Advanced biological systems to preserve native contextures in the human tumor microenvironment

Capturing the heterogeneity in tumor response and resistance

Simultaneously comparing multiple therapies for a single tumor

Generating high quality "big data" with orthogonal assays

 panCK CD8 CD3 CD68 Nucleus

Farcast proprietary image 

Farcast Human Tumor Microdynamics Platform

Farcast Biosciences develops pioneering anthropic (true-to-human) biological systems, data, and Artificial Intelligence (AI) to decipher the true complexities of human tumor dynamics. And make cancer treatment more predictive and precise.

iStock-1385929874.png

TruNet

Trusted relationships with network of global cancer centers for processing of multi-population tumor samples

iStock-1385930533.png
iStock-1385930831.png
Website Banner Farcast Bio.png

PRECISION BIOSIGNATURES PREDICT CLINICAL RESPONSE

The Farcast technology platform generates high quality, multimodal data from its advanced anthropic (true-to-human) systems to truly capture the complexity of tumor response and resistance to treatments. Treatment response and resistance “big data” are mined using the platform's AI capabilities to discover biosignatures with higher predictive power compared to simplistic biomarkers. Over 24,000 human tumors have been processed by the platform in multiple solid tumor types, across multiple mechanisms and diverse population cohorts.

Nature thumbnail thumb_edited.jpg
NEW
Nature Comm FEB 2024:
Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer
SITC 2023: Pre-Selection of patients who would respond to combination of chemotherapy and low dose immunotherapy using human histoculture platform

SITC 2023: Identification of effective treatment regimens for ovarian cancer using tumor histoculture platform

bottom of page